Literature DB >> 19807306

Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness?

Jasper M Bos, Maarten J Postma.   

Abstract

Year:  2004        PMID： 19807306     DOI： 10.1586/14737167.4.3.247

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN： 1473-7167            Impact factor:   2.217


× No keyword cloud information.
  9 in total

Review 1.  Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence.

Authors:  Petros Pechlivanoglou; Robin De Vries; Simon M G J Daenen; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2011-09       Impact factor: 4.981

Review 2.  Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines.

Authors:  Stefan Vegter; Cornelis Boersma; Mark Rozenbaum; Bob Wilffert; Gerjan Navis; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands.

Authors:  Maarten J Postma; Annoesjka Novak; Huib W K F H Scheijbeler; Marlene Gyldmark; Marianne L L van Genugten; Jan C Wilschut
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease.

Authors:  Mike van der Have; Bas Oldenburg; Herma H Fidder; Tim D G Belderbos; Peter D Siersema; Martijn G H van Oijen
Journal:  Dig Dis Sci       Date:  2013-08-15       Impact factor: 3.199

5.  Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.

Authors:  Robin de Vries; Simon Daenen; Keith Tolley; Axel Glasmacher; Archie Prentice; Sarah Howells; Hariette Christopherson; Lolkje T W de Jong-van den Berg; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

6.  Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model.

Authors:  Robin de Vries; Mirjam Kretzschmar; Joop F P Schellekens; Florens G A Versteegh; Tjalke A Westra; John J Roord; Maarten J Postma
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

7.  Pharmacoeconomic analysis in Saudi Arabia: an overdue agenda item for action.

Authors:  Abdulrazaq S Al-Jazairi; Nada S Al-Qadheeb; Aziza Ajlan
Journal:  Ann Saudi Med       Date:  2011 Jul-Aug       Impact factor: 1.526

8.  Willingness to pay for one quality-adjusted life year in Iran.

Authors:  Najmeh Moradi; Arash Rashidian; Shirin Nosratnejad; Alireza Olyaeemanesh; Marzieh Zanganeh; Leila Zarei
Journal:  Cost Eff Resour Alloc       Date:  2019-02-28

9.  Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?

Authors:  Montarat Thavorncharoensap; Yot Teerawattananon; Sirin Natanant; Wantanee Kulpeng; Jomkwan Yothasamut; Pitsaphun Werayingyong
Journal:  Clinicoecon Outcomes Res       Date:  2013-01-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.